ResMed Inc. ($RMD) Stock Forecast: Down 5.0% Today

What is ResMed Inc.?

ResMed Inc. (RMD) is a company specializing in medical devices, masks, and software for respiratory disorders, with a significant market presence in the United States. Today, the stock experienced a strong bearish movement.

Why is ResMed Inc. going down?

RMD stock is down 5.0% on May 1, 2026 16:20

• Several financial institutions adjusted their price targets for ResMed, with mixed reactions – one decreased while another increased the target. This variance in analyst sentiment could have impacted the bearish movement.
• Despite strong Q3 results and positive corporate developments including the acquisition of Noctrix and advancements in CPAP therapies, the market response may have been influenced by the overall analyst sentiment.
• The announcement of a quarterly dividend increase and ResMed's consistent financial performance were viewed positively. However, the stock's decline could be attributed to broader market conditions or investors taking profits.
• Additionally, external factors such as a recent cyberattack on a competitor could have contributed to the bearish movement of ResMed's stock.

RMD Price Chart

RMD Technical Analysis

RMD News

Mizuho Securities Adjusts ResMed Price Target to $235 From $255, Maintains Outperform Rating

Mizuho Securities has lowered its price target for ResMed (RMD) to $235 from $255, while reiterating an Outperform rating on the stock. This adjustment comes amidst a series of other analyst price target changes for ResMed, some increasing and some decreasing, following recent financial reports. ResMed specializes in medical devices, masks, and software for respiratory disorders, with a significant portion of its sales in the United States.

https://www.marketscreener.com/news/mizuho-securities-adjusts-resmed-price-target-to-235-from-255-maintains-outperform-rating-ce7f58d9dc8bfe24

RBC Raises Price Target on ResMed to $321 From $314, Keeps Outperform Rating

RBC has increased its price target for ResMed (RMD) to $321 from $314, while reaffirming an "Outperform" rating on the stock. This adjustment comes amidst other analysts also modifying their price targets for ResMed, some upward and some downward, as the company reported higher fiscal Q3 non-GAAP earnings and revenue. ResMed specializes in medical devices and software for respiratory disorders, with a significant presence in the United States.

https://www.marketscreener.com/news/rbc-raises-price-target-on-resmed-to-321-from-314-keeps-outperform-rating-ce7f58d9dd80f326

ResMed Inc. (NYSE:RMD) Plans Quarterly Dividend of $0.60

ResMed Inc. (NYSE:RMD) has declared a quarterly dividend of $0.60 per share, payable on June 18th to shareholders of record by May 14th, marking 13 consecutive years of dividend increases. The company exceeded earnings and revenue expectations for the last quarter, reporting $2.86 EPS and $1.43 billion in revenue, with analysts anticipating continued strong earnings to support future dividends. ResMed's dividend payout ratio is currently 22.7%, projected to decrease to 19.8% next year.

https://www.marketbeat.com/instant-alerts/resmed-inc-nysermd-plans-quarterly-dividend-of-060-2026-05-01/

ResMed Inc. (NYSE:RMD) Q3 2026 Earnings Call Transcript

ResMed Inc. reported strong Q3 fiscal year 2026 results with 11% revenue growth (8% constant currency) and 21% non-GAAP EPS growth, driven by operational excellence and innovation, particularly in fabric-based masks and the AirSense 11 platform. The company announced the acquisition of Noctrix for $340 million, expanding into restless leg syndrome treatment, and highlighted the positive impact of GLP-1 therapies on CPAP adherence and resupply. ResMed maintained its long-term outlook for high single-digit revenue growth and higher earnings growth, emphasizing its robust free cash flow and commitment to shareholder returns.

https://www.insidermonkey.com/blog/resmed-inc-nysermd-q3-2026-earnings-call-transcript-1752115/

Stryker results miss after Q1 cyberattack, company sticks with guidance

Stryker reported first-quarter results that missed Wall Street analyst consensus due to a significant cyberattack by Iran-backed hackers in early March. Despite the operational disruption, the company is maintaining its full-year 2026 guidance, citing strong market fundamentals. Stryker also announced organizational changes, combining orthopedic instruments and Mako surgical robotics into a new Ortho Tech business, and its intention to acquire Amplitude Vascular Systems.

https://www.massdevice.com/stryker-results-miss-after-q1-cyberattack/

Trending Today

Brent Crude Oil ($BRENT) Commodity Forecast: Down 5.9% Today

Arista Networks Inc. ($ANET) Stock Forecast: Down 15.7% Today

Lam Research Corporation ($LRCX) Stock Forecast: Up 7.5% Today

Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Down 6.0% Today

Super Micro Computer Inc ($SMCI) Stock Forecast: Up 23.2% Today

Upstart Holdings Inc. ($UPST) Stock Forecast: Down 9.5% Today

Internationa Flavors & Fragrances Inc. ($IFF) Stock Forecast: Up 17.2% Today

Circle Internet Group ($CRCL) Stock Forecast: Up 6.0% Today

Devon Energy Corporation ($DVN) Stock Forecast: Down 8.6% Today

Taiwan Semiconductor Manufacturing Company Ltd. ($TSM) Stock Forecast: Up 6.3% Today

ResMed Inc. Price History

30.00.2026 - RMD Stock was down 0.8%

• The strong bearish movement in ResMed's stock today could be attributed to profit-taking by investors after a period of positive performance and price appreciation.
• Despite the impressive Q2 results and increased institutional interest in the company's stock, the notable insider selling by CEO Michael J. Farrell and others might have raised concerns among investors about the future outlook of the company.
• Additionally, the market may be reacting to the Hold rating reiterated by an independent analyst, indicating a more cautious stance on the stock despite the positive financial performance.
• Overall, the bearish movement could be a result of a combination of factors, including profit-taking, insider selling, and cautious analyst sentiment, leading to a temporary dip in the stock price.

13.00.2026 - RMD Stock was down 0.3%

• Bogart Wealth LLC notably increased its stake in ResMed Inc., while company insiders have been selling shares possibly suggesting differing views on the company's potential.
• ResMed's robust Q3 earnings report and revenue growth might have initially boosted investor confidence, but recent insider selling by the CEO and a director could have raised concerns.
• The sale of shares by ResMed director Peter C. Farrell under a pre-arranged trading plan, amid varied analyst ratings, could have intensified the negative sentiment surrounding the stock.
• Despite the positive earnings and institutional investments, the mixture of analyst ratings, insider selling, and market apprehensions about the company's future likely contributed to the bearish movement in ResMed's stock price today.

05.00.2026 - RMD Stock was up 1.3%

• The significant insider selling and institutional ownership of ResMed Inc. could have initially raised concerns among investors, but the company's ability to surpass EPS and revenue expectations likely reassured the market.
• ResMed's strategic shift towards a connected ecosystem for sleep and respiratory care may have sparked investor optimism about the company's long-term growth potential and competitive edge.
• The high institutional ownership, particularly with influential shareholders like The Vanguard Group, Inc., suggests a level of confidence in ResMed's future performance, potentially contributing to the bullish movement in the stock.
• Overall, the combination of positive financial results, strategic positioning in the market, and strong institutional support likely drove the bullish momentum in ResMed's stock today.

01.04.2026 - RMD Stock was down 5.0%

• Several financial institutions adjusted their price targets for ResMed, with mixed reactions – one decreased while another increased the target. This variance in analyst sentiment could have impacted the bearish movement.
• Despite strong Q3 results and positive corporate developments including the acquisition of Noctrix and advancements in CPAP therapies, the market response may have been influenced by the overall analyst sentiment.
• The announcement of a quarterly dividend increase and ResMed's consistent financial performance were viewed positively. However, the stock's decline could be attributed to broader market conditions or investors taking profits.
• Additionally, external factors such as a recent cyberattack on a competitor could have contributed to the bearish movement of ResMed's stock.

01.04.2026 - RMD Stock was down 5.7%

• Today, there was a significant downward movement in ResMed's stock, potentially due to the Q3 2026 results showing mixed performance: surpassing expectations in EPS growth but falling short in revenue.
• The market reacted negatively to the revenue miss despite the company exceeding earnings forecasts and reporting increased revenue, leading to a bearish trend in the stock.
• Factors such as the acquisition of Noctrix for $340 million, the CFO's retirement announcement, and the focus on GLP-1 therapies may have created uncertainty among investors, contributing to the decline in the stock price.
• The stable stock performance in aftermarket trading following the mixed results could be causing concern about the company's future growth prospects and competitiveness in the market.

04.01.2026 - RMD Stock was up 2.6%

• Institutional investors acquiring significant stakes in ResMed Inc. indicate growing confidence in the company's future prospects, contributing to the bullish movement.
• Despite insider selling trends, the positive quarterly results and dividend announcement have likely boosted investor sentiment towards ResMed.
• Emphasizing ResMed as a stable long-term investment in the healthcare sector reinforces the positive market movement, attracting more investors to the stock.
• The overall bullish sentiment towards ResMed is further supported by the insider sell alert, which, despite the selling activity, did not deter investors, possibly due to the company's strong fundamentals and growth potential.

25.02.2026 - RMD Stock was down 3.2%

• A downgrade from Buy to Hold may have influenced investor sentiment, leading to a sell-off of ResMed's shares.
• Despite maintaining a Buy rating and a positive outlook, the market might have reacted more strongly to the rating change.
• An increased stake by Nordea Investment Management indicates long-term confidence in ResMed but short-term market dynamics could have overshadowed this positive development.
• The FDA approval of LivaNova's aura6000 System for OSA treatment may have created some competition concerns among investors, impacting ResMed's stock performance negatively.

11.01.2026 - RMD Stock was down 6.1%

• Significant selling activity by Baader Bank Aktiengesellschaft and CEO Michael Farrell, reducing their stakes in ResMed, might have signaled a lack of confidence in the company's future performance, contributing to the bearish trend.
• Despite ResMed's strong quarterly results and analyst recommendations, insider selling totaling over $4.6 million could have raised concerns among investors about the company's growth potential.
• The high institutional ownership of 73% in ResMed indicates that any changes in their positions could heavily influence the stock price, potentially leading to a bearish sentiment as seen today.
• A comparison with Ross Stores in discussions about market interest highlights the contrasting performance and market perception between the two companies, potentially leading investors to shift their focus away from ResMed, contributing to the bearish movement.

12.01.2026 - RMD Stock was down 5.1%

• The stock's decline could be linked to CEO Michael Farrell selling a significant number of shares, leading to investor concerns regarding the company's future.
• The reduction in ResMed's stake by Baader Bank Aktiengesellschaft may have also fueled negative sentiment, despite the company surpassing quarterly expectations.
• Market reaction to the ongoing clinical trial of ResMed's new software tool for sleep apnea patients might be influencing investor decisions, awaiting substantial results.
• Insider selling, institutional adjustments, and trial progress are potential factors contributing to today's bearish movement in ResMed's stock.